Capital International Sarl Reduces Stake in Regeneron Pharmaceuticals

Institutional investor decreases holdings in biopharmaceutical company by 13.1% in third quarter

Mar. 10, 2026 at 11:38am

Got story updates? Submit your updates here. ›

Capital International Sarl, an institutional investor, decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.1% during the third quarter, according to a recent SEC filing. The firm now owns 46,792 shares of the biopharmaceutical company's stock, valued at $26,310,000.

Why it matters

Regeneron Pharmaceuticals is a prominent biopharmaceutical company known for its innovative drug discovery technologies and pipeline of therapies. Changes in institutional ownership can provide insights into market sentiment and investment trends around the company's stock.

The details

According to the SEC filing, Capital International Sarl sold 7,027 shares of Regeneron Pharmaceuticals during the third quarter, reducing its total holdings to 46,792 shares. The firm cited portfolio rebalancing as the reason for the decrease in its Regeneron position.

  • The SEC filing was submitted on March 10, 2026, covering the third quarter of 2025.

The players

Capital International Sarl

An institutional investor that decreased its stake in Regeneron Pharmaceuticals by 13.1% in the third quarter of 2025.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Capital International Sarl's Regeneron Pharmaceuticals holdings suggests a potential shift in the institutional investor's outlook on the biopharmaceutical company, though the specific reasons behind the portfolio adjustment are not clear from the available information.